Browsing by author "Jones, Robin"
Now showing items 21-40 of 54
-
Epithelioid malignant peripheral nerve sheath tumor arising in schwannoma.
Heatley, N; Kolson Kokohaare, E; Strauss, DC; Hallin, M; Jones, RL; et al. (SAGE PUBLICATIONS LTD, 2020-08-01)Epithelioid malignant peripheral nerve sheath tumor (EMPNST, malignant epithelioid schwannoma) is a rare variant of malignant peripheral nerve sheath tumor that has morphologic and immunophenotypic overlap with a variety ... -
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study.
Constantinidou, A; Sauve, N; Stacchiotti, S; Blay, J-Y; Vincenzi, B; et al. (ELSEVIER, 2020-07-01)INTRODUCTION: Angiosarcomas constitute approximately 2% to 3% of all soft tissue sarcomas, are characterised by an aggressive clinical behaviour and poor outcome. Optimal management of localised angiosarcomas consists of ... -
Extraskeletal osteosarcomas: current update.
Kattepur, AK; Gulia, A; Jones, RL; Rastogi, SExtraskeletal osteosarcoma is a very infrequently diagnosed soft-tissue sarcoma subtype which has identical histological features to bone osteosarcoma. However, its demographics, presentation, radiology and treatment ... -
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder, M; Abdul Razak, AR; Gilligan, AM; Leong, H; Ma, X; et al. (2021-04-15)Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the ... -
IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli, K; Yao, L; Nowicki, TS; Zhang, S; Black, RG; et al.Background Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are ideal solid tumors for the development of adoptive cellular therapy (ACT) targeting NY-ESO-1, as a high frequency of tumors homogeneously express ... -
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients.
Schroeder, BA; Zhang, Y; Smythe, KS; Desai, P; Thomas, A; et al. (2022-03-02)Patients with metastatic soft tissue sarcoma (STS) have a poor prognosis and few available systemic treatment options. Trabectedin is currently being investigated as a potential adjunct to immunotherapy as it has been ... -
Inflammatory Myofibroblastic Tumour: State of the Art.
Gros, L; Dei Tos, AP; Jones, RL; Digklia, A (MDPI, 2022-07-27)An inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by inflammatory cells, including lymphocytes and eosinophils. It is an ultra-rare tumor, the ... -
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated ... -
Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.
Goff, PH; Riolobos, L; LaFleur, BJ; Spraker, MB; Seo, YD; et al.<h4>Purpose</h4>To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.<h4>Experimental ... -
On the road to improved outcomes by capturing leiomyosarcoma patients' views.
Jones, RL (FUTURE MEDICINE LTD, 2022-10-03)An international collaborative project set up as a 'priority setting partnership' used a questionnaire to capture the views of patients, carers and clinicians about the sarcoma research agenda. Responses from 25 patients ... -
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger, E; Litière, S; Le Cesne, A; Mir, O; Gelderblom, H; et al. (2018-10)BACKGROUND:Almost half of patients diagnosed with soft tissue sarcoma (STS) are older than 65 years; however, the outcomes of elderly patients with metastatic disease are not well described. PATIENTS AND METHODS:An elderly ... -
p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?
Noujaim, J; Gonzalez, D; Thway, K; Jones, RL; Judson, I (2016-05)Exon 11 KIT mutations are found in a majority of gastrointestinal stromal tumors (GIST) and are usually predictive of response to imatinib, a KIT, PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to imatinib ... -
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár, A; Jones, RL; Stacchiotti, S; Gelderblom, H; Guida, M; et al. (2017-01)Background Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy ... -
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs, Z; Messiou, C; Wong, HH; Hatcher, H; Miah, A; et al. (2017-04)Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of ... -
Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld, A; Radia, U; Goggin, C; Mahalingam, P; Benson, C; et al. (TAYLOR & FRANCIS LTD, 2022-09-15)INTRODUCTION: Anthracycline chemotherapeutic agents are widely used in the treatment of hematological and solid tumors, working principally through DNA intercalation and topoisomerase II inhibition. However, they are also ... -
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones, RL; Chawla, SP; Attia, S; Schöffski, P; Gelderblom, H; et al. (WILEY, 2019-07-15)BACKGROUND: Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is ... -
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah, N; Chawla, SP; Block, MS; Morris, JC; Do, K; et al. (TAYLOR & FRANCIS INC, 2020-11-19)Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has ... -
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Jones, RL; Le Cesne, A; Ibrahim, T; Garcia Del Muro, X; Menge, F (2018-12)Introduction Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely ... -
Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase ... -
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Jones, RL; Wagner, AJ; Kawai, A; Tamura, K; Shahir, A; et al. (2021-02-25)Purpose Few prospective studies have assessed anthracycline-associated cardiotoxicity in patients with sarcoma. We evaluated cardiotoxicity in patients with soft-tissue sarcomas administered doxorubicin in the phase III ...